SpringWorks Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
SpringWorks Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||||||
| product revenue | 49,087,000 | 61,549,000 | 49,301,000 | 40,186,000 | 21,006,000 | ||||||||||||||||||
| total revenue | 49,087,000 | 61,549,000 | 49,301,000 | 59,733,000 | 21,006,000 | ||||||||||||||||||
| yoy | 133.68% | ||||||||||||||||||||||
| qoq | -20.25% | 24.84% | -17.46% | 184.36% | |||||||||||||||||||
| operating costs and expenses: | |||||||||||||||||||||||
| cost of product revenue | 3,527,000 | 5,554,000 | 3,341,000 | 2,453,000 | 1,202,000 | ||||||||||||||||||
| selling, general and administrative | 76,501,000 | 77,099,000 | 61,601,000 | 57,839,000 | 60,113,000 | ||||||||||||||||||
| research and development | 49,595,000 | 60,238,000 | 42,296,000 | 44,362,000 | 53,622,000 | 43,652,000 | 37,453,000 | 35,858,000 | 33,524,000 | 37,928,000 | 36,067,000 | 38,024,000 | 34,103,000 | 29,344,000 | 22,866,000 | 32,091,000 | 17,375,000 | 15,262,000 | 13,923,000 | 12,947,000 | 9,727,000 | 12,172,000 | 10,745,000 |
| total operating costs and expenses | 129,623,000 | 81,707,250 | 107,238,000 | 104,654,000 | 114,937,000 | ||||||||||||||||||
| income from operations | -80,536,000 | -81,342,000 | -57,937,000 | -44,921,000 | -93,931,000 | -98,463,000 | -83,999,000 | -82,852,000 | -77,699,000 | -78,454,000 | -71,740,000 | -69,011,000 | -61,469,000 | -55,796,000 | -40,895,000 | -47,021,000 | -29,756,000 | 11,219,000 | -21,592,000 | -19,821,000 | -16,130,000 | -17,371,000 | -15,329,000 |
| yoy | -14.26% | -17.39% | -31.03% | -45.78% | 20.89% | 25.50% | 17.09% | 20.06% | 26.40% | 40.61% | 75.42% | 46.77% | 106.58% | -597.33% | 89.40% | 137.23% | 84.48% | -164.58% | 40.86% | ||||
| qoq | -0.99% | 40.40% | 28.98% | -52.18% | -4.60% | 17.22% | 1.38% | 6.63% | -0.96% | 9.36% | 3.95% | 12.27% | 10.17% | 36.44% | -13.03% | 58.02% | -365.23% | -151.96% | 8.93% | 22.88% | -7.14% | 13.32% | |
| operating margin % | -164.07% | -132.16% | -117.52% | -75.20% | -447.16% | ||||||||||||||||||
| interest and other income: | |||||||||||||||||||||||
| interest and other income | -998,000 | 5,435,000 | 6,216,000 | 6,778,000 | 7,571,000 | ||||||||||||||||||
| total interest and other income | -998,000 | 5,435,000 | 6,216,000 | 6,778,000 | 7,571,000 | 5,976,000 | 5,586,000 | 5,828,000 | 5,557,000 | 4,956,000 | 838,000 | 348,000 | 5,000 | 130,250 | 121,000 | 170,000 | 230,000 | ||||||
| equity method investment loss | -1,653,000 | -1,390,000 | -1,809,000 | -1,776,000 | -1,025,000 | ||||||||||||||||||
| net income | -83,187,000 | -77,297,000 | -53,530,000 | -39,919,000 | -87,385,000 | -94,322,000 | -79,437,000 | -77,925,000 | -73,420,000 | -74,178,000 | -72,388,000 | -69,050,000 | -61,801,000 | -56,072,000 | -41,041,000 | -47,010,000 | -29,787,000 | 11,272,000 | -21,659,000 | -19,893,000 | -15,294,000 | -16,217,000 | -16,833,000 |
| yoy | -4.80% | -18.05% | -32.61% | -48.77% | 19.02% | 27.16% | 9.74% | 12.85% | 18.80% | 32.29% | 76.38% | 46.88% | 107.48% | -597.44% | 89.49% | 136.31% | 94.76% | -169.51% | 28.67% | ||||
| qoq | 7.62% | 44.40% | 34.10% | -54.32% | -7.35% | 18.74% | 1.94% | 6.14% | -1.02% | 2.47% | 4.83% | 11.73% | 10.22% | 36.62% | -12.70% | 57.82% | -364.26% | -152.04% | 8.88% | 30.07% | -5.69% | -3.66% | |
| net income margin % | -169.47% | -125.59% | -108.58% | -66.83% | -416.00% | ||||||||||||||||||
| net income per share | -1.11 | -1.04 | -0.72 | -0.54 | -1.18 | -1.45 | -1.27 | -1.25 | -1.18 | -1.17 | -1.37 | -1.41 | -1.26 | -1.16 | -0.84 | -0.97 | -0.62 | 0.3 | -0.51 | -0.47 | -0.37 | 5.43 | -1.77 |
| weighted-average common shares outstanding, basic and diluted | 74,885,348 | 74,132,811 | 74,264,501 | 74,121,014 | 73,768,603 | 63,123,936 | 62,521,772 | 62,464,081 | 62,326,992 | 53,290,528 | 52,900,819 | 49,071,590 | 48,937,756 | 48,497,790 | 48,595,420 | 48,422,921 | 48,229,539 | 43,300,063 | 42,148,837 | 41,945,058 | 41,789,120 | 13,274,836 | 9,487,329 |
| other revenue | 19,547,000 | ||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||
| general and administrative | 34,428,750 | 46,546,000 | 46,994,000 | 44,175,000 | 40,526,000 | 35,673,000 | 30,987,000 | 27,366,000 | 26,452,000 | 18,029,000 | 14,930,000 | 12,381,000 | 8,519,000 | 7,669,000 | 6,874,000 | 6,403,000 | 5,199,000 | 4,584,000 | |||||
| total operating expenses | 103,910,000 | 83,999,000 | 82,852,000 | 77,699,000 | 78,454,000 | 71,740,000 | 69,011,000 | 61,469,000 | 55,796,000 | 40,895,000 | 47,021,000 | 29,756,000 | 23,781,000 | 21,592,000 | 19,821,000 | 16,130,000 | 17,371,000 | 15,329,000 | |||||
| other income | -93,250 | -76,000 | -98,000 | -199,000 | 153,000 | -74,000 | -24,000 | -193,000 | -56,000 | -58,000 | -41,000 | 3,000 | |||||||||||
| interest income | 4,336,000 | 5,662,000 | 5,926,000 | 5,756,000 | 4,803,000 | 912,000 | 372,000 | 198,000 | 81,000 | 179,000 | 211,000 | 227,000 | 174,000 | 63,000 | 157,000 | 936,000 | 1,267,000 | 997,000 | |||||
| equity investment loss | -800,750 | -1,024,000 | -901,000 | -1,278,000 | -680,000 | -1,486,000 | -387,000 | -337,000 | -301,000 | -267,000 | -159,000 | -261,000 | -146,000 | -130,000 | -229,000 | -100,000 | -113,000 | -2,501,000 | |||||
| | |||||||||||||||||||||||
| other income: | |||||||||||||||||||||||
| total other income | 199,000 | 63,000 | 157,000 | 936,000 | 1,267,000 | 997,000 | |||||||||||||||||
| reconciliation of net income to net income attributable to common stockholders: | |||||||||||||||||||||||
| net gain attributable to extinguishment of series a convertible preferred and junior series a convertible preferred units | |||||||||||||||||||||||
| net income attributable to common stockholders | -14,211,500 | -21,659,000 | -19,893,000 | ||||||||||||||||||||
| net income attributable to common stockholders, basic and diluted | -15,294,000 | -16,217,000 | -16,833,000 | ||||||||||||||||||||
| net gain attributable to extinguishment of series a convertible preferred and junior series a convertible preferred shares | 1,932,250 | ||||||||||||||||||||||
| net income per unit, basic and diluted | |||||||||||||||||||||||
| weighted-average common units outstanding, basic and diluted |
We provide you with 20 years income statements for SpringWorks Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SpringWorks Therapeutics stock. Explore the full financial landscape of SpringWorks Therapeutics stock with our expertly curated income statements.
The information provided in this report about SpringWorks Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.